X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Manufacturing

Forecasting Biopharma Contract Manufacturing Trends In 2022

Content Team by Content Team
25th August 2022
in Manufacturing, News
Integrity Bio Announces Newly Validated Biotech Manufacturing Line

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

A recent survey found that 86.9% of biopharmaceutical businesses outsource at least a portion of their operations, which has contributed to the $14 billion market for biopharmaceutical contract manufacturing.

Over the next ten years, the investigators predict a very bright and lucrative destiny for biopharmaceutical contract development and manufacturing organisations (CDMOs).

The study discovered that, despite the fact that the number of outsourced activities was increasing from 18 in 2020 to 26 in 2019, the majority of these activities remained skilled, routine, non-core, or less technical in nature. Examples include fill and finish, analytical as well as sterility testing, and routine testing. Analytical testing- other bioassays (86.9%), toxicity testing (79.4%), validation services (75.7%), product characterization testing (72.9%), and cell line stability testing (67.3%) were the five most outsourced jobs.

The study also demonstrates that the market appears to view process development duties as internal activities that cannot or should not be outsourced. Design of experiments (DoE), downstream process development, and upstream process development were among the least outsourced jobs (46.7%). The paper, however, makes the case that outsourcing bioprocessing will be crucial as businesses look to cut costs and speed up time to market.

With 39.6% of non-US respondents saying they would outsource manufacturing to US-based facilities, the US continues to be the most common outsourcing destination. Although 30% of respondents indicated they will export >50% of clinical trials and activities to India, China, or other lower-cost nations within the next five years. Notably, China and India are expected to engage in severe competition over the coming decade.

While up until now, outsourcing to CDMOs in developing nations has frequently involved less regulated, smaller-scale R&D, vetting, method development, and manufacturing of research reactants and pre-clinical supplies, it is anticipated that China will become an increasingly popular location for production outsourcing in the coming years.

The report identifies several key trends in biopharmaceutical outsourcing, including an increase in outsourcing to developing countries like China and India; small businesses needing contract partners to support their role as the primary sources of innovation; a rise in the use of single-use technologies because of their adaptability and lower cost; and a change in industry leadership as more players enter the market.

The main criteria that businesses consider when outsourcing the production of biopharmaceuticals are adherence to global good manufacturing practise (GMP) standards, intellectual property protection property, adherence to the firm’s standards of quality, pricing/cost of services, and a track record of success.

According to the researchers, the market requires a massive expansion of CDMO facilities and capacity for cutting-edge technologies including cell and gene therapies as well as antibody-drug conjugates (ADCs). While researchers acknowledged that the COVID-19 pandemic vaccine and treatment production is presently consuming much of the industry’s flexible capacity, they predicted that as consumption moderates, capacity will normalise, allowing other items to be prioritised.

Previous Post

Usual Pharma Compliance Issues Noted In FDA Warning Letters

Next Post

Pharma Contract Manufacturing Market To Be $130bn By 2026

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
Pharma Contract Manufacturing Market To Be $130bn By 2026

Pharma Contract Manufacturing Market To Be $130bn By 2026

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In